Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential TPN and Nivolumab + Radiation in Advanced Laryngeal/Hypopharyngeal Cancer
NCT03894891Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2019
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in laryngeal squamous cell carcinoma (LSCC), hypopharyngeal squamous cell carcinoma (HSCC), sponsored by Dana-Farber Cancer Institute. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
laryngeal squamous cell carcinoma (LSCC)hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT03894891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894891.